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Abstract			Human	cytomegalovirus	(HCMV)	is	an	important	opportunistic	pathogen	in	28	
immunocompromised	patients	and	a	major	cause	of	congenital	birth	defects	when	acquired	in	utero.	In	29	
the	1990s,	four	chimeric	viruses	were	constructed	by	replacing	genome	segments	of	the	high	passage	30	
Towne	strain	with	segments	of	the	low	passage	Toledo	strain,	with	the	goal	of	obtaining	live	attenuated	31	
vaccine	candidates	that	remained	safe	but	were	more	immunogenic	than	the	overly	attenuated	Towne	32	
vaccine.	The	chimeras	were	found	to	be	safe	when	administered	to	HCMV-seronegative	human	33	
volunteers,	but	to	differ	significantly	in	their	ability	to	induce	seroconversion.	This	suggests	that	34	
chimera-specific	genetic	differences	impacted	the	ability	to	replicate	or	persist	in	vivo	and	the	35	
consequent	ability	to	induce	an	antibody	response.	To	identify	specific	genomic	breakpoints	between	36	
Towne	and	Toledo	sequences	and	establish	whether	spontaneous	mutations	or	rearrangements	had	37	
occurred	during	construction	of	the	chimeras,	complete	genome	sequences	were	determined.	No	major	38	
deletions	or	rearrangements	were	observed,	although	a	number	of	unanticipated	mutations	were	39	
identified.	However,	no	clear	association	emerged	between	the	genetic	content	of	the	chimeras	and	the	40	
reported	levels	of	vaccine-induced	HCMV-specific	humoral	or	cellular	immune	responses,	suggesting	41	
that	multiple	genetic	determinants	are	likely	to	impact	immunogenicity.	In	addition	to	revealing	the	42	
genome	organization	of	the	four	vaccine	candidates,	this	study	provided	an	opportunity	to	probe	the	43	
genetics	of	HCMV	attenuation	in	humans.	The	results	may	be	valuable	in	the	future	design	of	safe	live	or	44	
replication-defective	vaccines	that	optimize	immunogenicity	and	efficacy.	45	
	46	
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	48	
Human	cytomegalovirus	(HCMV)	infections	are	an	important	cause	of	birth	defects	among	newborns	49	
infected	in	utero	and	of	morbidity	and	mortality	in	transplant	and	AIDS	patients.	Despite	receiving	the	50	
US	Institute	of	Medicine’s	highest	priority	designation	in	2000	(1),	and	after	half	a	century	of	research,	51	
development	of	an	HCMV	vaccine	remains	an	unmet	medical	need	of	considerable	importance	to	public	52	
health.		53	
Among	the	first	HCMV	vaccine	candidates	was	the	live	attenuated	strain	Towne	vaccine	produced	by	54	
>125	passages	in	cultured	human	fibroblasts	(2).	This	vaccine	has	been	administered	safely	to	nearly	55	
1,000	human	subjects	at	doses	as	high	as	3,000	plaque-forming	units	(pfu),	and	has	never	been	56	
recovered	from	an	immunized	subject,	even	following	immune	suppression	(3-5).	In	contrast,	the	Toledo	57	
strain	passaged	only	4	or	5	times	in	cultured	fibroblasts	exhibited	virulence	characteristics	in	HCMV-58	
seronegative	volunteers	at	a	dose	of	only	10	pfu	(6),	and	was	capable	of	superinfection,	replicating,	and	59	
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persisting	in	the	context	of	pre-existing	natural	immunity	(6,	7).	Although	administration	of	Towne	60	
vaccine	prior	to	renal	transplantation	reduced	post-transplant	HCMV-associated	disease,	it	did	not	61	
prevent	HCMV	infections	(3),	and	it	failed	to	protect	immunocompetent	mothers	from	acquiring	HCMV	62	
infections	from	their	children	(8).		These	results	suggest	that	the	immunogenicity	of	the	Towne	vaccine	63	
may	be	overly	attenuated	due	to	mutations	acquired	during	serial	passage	in	vitro	(9-11).	64	
With	the	goal	of	increasing	the	immunogenicity	of	the	Towne	vaccine,	four	genetic	chimeras	were	65	
constructed	by	systematically	replacing	Towne	genome	segments	with	segments	from	Toledo	(12).	Each	66	
chimera	was	shown	to	be	safe	when	administered	at	a	dose	of	1,000	pfu	to	healthy	HCMV-seropositive	67	
human	volunteers.	However,	failure	to	recover	any	chimera	from	blood,	urine,	or	saliva	following	68	
inoculation,	combined	with	the	inability	of	the	chimeras	to	boost	humoral	or	cellular	immune	responses,	69	
suggested	that	none	retained	the	superinfection	properties	of	the	Toledo	strain	(12).	70	
A	phase	1	trial	of	the	four	chimeras	in	healthy	HCMV-seronegative	subjects	was	recently	completed	71	
(13).	Each	vaccine	was	administered	to	a	total	of	nine	subjects,	with	groups	of	three	subjects	receiving	72	
doses	of	10,	100,	or	1,000	pfu	by	the	subcutaneous	route.	There	were	neither	local	nor	systemic	73	
reactions	nor	serious	adverse	events,	and	none	of	the	subjects	shed	infectious	virus	in	urine	or	saliva.	In	74	
general,	cellular	and	humoral	immune	responses	were	comparable	to	those	reported	previously	for	the	75	
Towne	vaccine,	and	none	of	the	chimeras	appeared	to	be	more	virulent	or	immunogenic	than	the	76	
Towne	vaccine.	However,	with	regard	to	seroconversion,	chimeras	2	and	4	were	clearly	more	77	
immunogenic	than	chimeras	1	or	3:	seven	of	the	nine	subjects	who	received	chimera	4	seroconverted,	78	
as	did	three	of	the	nine	subjects	who	received	chimera	2,	while	only	one	of	the	nine	subjects	who	79	
received	chimera	1	seroconverted,	and	none	of	the	nine	subjects	who	received	chimera	3	seroconverted	80	
(13).	81	
These	results	suggest	that	genetic	differences	among	the	four	chimeras	significantly	impacted	their	82	
ability	to	replicate	or	persist	in	vivo	to	an	extent	necessary	to	induce	an	antibody	response.	Although	the	83	
approximate	locations	of	junctions	between	Towne	and	Toledo	sequences	in	the	chimeras	have	been	84	
reported	(12),	the	precise	breakpoints	and	any	spontaneous	mutations	that	may	have	arisen	during	85	
recombinant	virus	construction	were	unknown.	Therefore,	we	determined	the	complete	sequences	of	86	
all	four	chimeras.	87	
Table	1	summarizes	genome	information	for	the	chimeras	and	complete	(or	substantially	complete)	88	
Towne	and	Toledo	sequences	that	were	derived	previously	or	during	the	present	study.	The	Towne	89	
genomes	represent	two	major	variants,	of	which	varS,	in	comparison	with	varL,	has	a	large	deletion	at	90	
the	right	end	of	the	UL	region	(commonly	called	UL/b'	(11))	associated	with	an	inverted	duplication	of	a	91	
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sequence	from	the	left	end	of	UL	(9).	Passage	of	HCMV	in	cell	culture	is	known	invariably	to	result	in	92	
mutation	of	RL13	and	also	of	UL128,	UL130,	or	UL131A	(14-16),	the	latter	three	genes	encoding	subunits	93	
of	a	pentameric	complex	necessary	for	efficient	entry	of	HCMV	into	cells	of	the	epithelial,	endothelial,	or	94	
myeloid	lineages	(17-22).	Towne	is	mutated	in	RL13	and	UL130,	as	well	as	in	UL1,	UL40,	and	US1	(9,	10),	95	
and	the	form	of	varS	from	which	the	chimeras	were	derived	is	also	mutated	in	UL36	(23).	Toledo	is	96	
mutated	in	RL13	and	UL128	(the	latter	by	the	inversion	of	a	large	region	of	the	genome)	(11,	24,	25),	as	97	
well	as	in	UL9.	Mapping	the	components	of	the	chimeras	was	informed	in	particular	by	accessions	98	
FJ616285	and	GQ121041	for	Towne	(9,	10)	and	accessions	GU937742	and	KY002201	for	Toledo.	99	
GU937742	represents	the	standard	form	of	Toledo	from	which	the	chimeras	were	derived	(at	passage	100	
8),	and	KY002201	represents	a	variant	(obtained	via	transfection	of	a	Toledo	DNA	stock	followed	by	101	
plaque	purification)	that	has	a	different	mutation	in	gene	RL13.	The	fact	that	more	than	one	RL13	102	
mutant	was	selected	during	isolation	of	Toledo	is	consistent	with	similar	observations	made	with	other	103	
strains,	and	indicates	that	adaptation	of	wild-type	HCMV	to	cell	culture	involves	a	complex,	gradual	104	
process	of	genetic	selection	(14-16).	Thus,	both	Towne	and	Toledo	apparently	carried	mutations	that	105	
had	accumulated	due	to	passage	in	fibroblasts.		106	
The	genetic	maps	of	the	chimeras	are	shown	in	Figure	1A.	The	parental	strains	are	both	non-107	
epitheliotropic	and	non-endotheliotropic	due	to	the	mutations	disrupting	expression	of	UL130	(Towne)	108	
or	UL128	(Toledo)	(10,	17,	26).	The	consequent	failure	to	express	a	functional	pentameric	complex	is	109	
speculated	to	contribute	to	attenuation	of	the	Towne	vaccine	by	limiting	the	range	of	host	cell	types	110	
available	for	replication	in	vivo,	and	to	Towne's	insufficient	efficacy,	as	the	pentameric	complex	is	an	111	
important	immunogen	for	eliciting	antibodies	that	neutralize	the	entry	of	HCMV	into	cells	of	the	112	
epithelial,	endothelial,	and	myeloid	lineages	(22,	27-29).	113	
By	design	(12),	all	four	chimeras	contain	Toledo	UL/b'	and	within	this	a	disrupted	copy	of	UL128.	114	
However,	prior	to	the	present	study	it	was	unclear	whether	chimeras	1	and	2	might	contain	an	intact	115	
copy	of	UL128	within	the	upstream	Towne	sequences,	potentially	rendering	them	epitheliotropic	and	116	
endotheliotropic.	However,	as	the	sequence	data	indicate	that	Towne	UL128	is	absent	from	all	four	117	
chimeras,	none	of	them	is	genetically	capable	of	expressing	a	functional	UL128	protein	or	pentameric	118	
complex,	even	though	the	UL130	and	UL131A	proteins,	which	contain	neutralizing	epitopes	(30),	may	be	119	
expressed.	Consistent	with	this,	phenotypic	analysis	revealed	that	all	four	chimeras	fail	to	enter	ARPE-19	120	
epithelial	cells	efficiently	(Figure	1B	and	(31)).	By	extension,	the	inability	to	express	the	pentameric	121	
complex	is	consistent	with	the	phase	1	trial	findings	that	the	chimera	vaccines	induced	neutralizing	titers	122	
to	entry	into	epithelial	cells	similar	to	those	of	Towne	and	significantly	lower	than	those	induced	by	123	
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natural	infection	(13).	In	addition	to	the	previously	recognized	mutations	in	the	parental	strains,	the	124	
sequences	revealed	three	novel	mutations.	The	first	disrupts	UL147A	in	chimera	4,	the	second	is	a	short	125	
duplication	within	the	Towne-derived	noncoding	RNA4.9	in	chimeras	1,	3,	and	4	(with	two	duplications	126	
in	chimera	4),	and	the	third	is	an	intragenic	deletion	between	US34A	and	TRS1	in	chimera	1.	A	few	other	127	
minor	differences	were	also	noted,	as	specified	in	the	legend	to	Figure	1.	128	
Examination	of	the	mutations	highlighted	in	Figure	1A	revealed	no	obvious	association	between	the	129	
presence	of	particular	mutations	and	the	efficacy	of	the	chimeras	in	inducing	seroconversion.	For	130	
example,	the	fact	that	chimeras	2	and	3	contain	the	same	mutations	except	for	one	impacting	UL40	131	
might	suggest	that	an	inability	to	express	UL40	renders	chimera	3	unable	to	induce	seroconversion.	132	
However,	the	same	mutation	is	present	in	chimera	4,	which	is	the	most	immunogenic	of	the	vaccines.	133	
Indeed,	each	of	the	mutations	present	in	chimera	3	is	also	present	in	immunogenic	chimeras	2	or	4.	134	
Therefore,	the	ability	to	induce	seroconversion	is	likely	associated	with	the	distribution	of	parental	135	
sequences	among	the	chimeras	rather	than	with	specific	mutations.	For	example,	sequences	from	US16	136	
to	the	right	genome	terminus	are	derived	from	Toledo	in	chimera	4	and	from	Towne	in	the	other	137	
chimeras.	This	region	contains	immune	evasion	genes	(32)	and	perhaps	other	elements	that	may	138	
contribute	to	the	relatively	enhanced	immunogenicity	of	chimera	4.		139	
Although	the	phase	1	chimera	trial	did	not	include	Towne	vaccine,	comparison	to	historical	data	140	
suggested	that	all	four	chimeras	are	attenuated	to	a	level	similar	to	that	of	the	Towne	vaccine	(13).	This	141	
indicates	that	the	virulence	characteristics	associated	with	Toledo	are	multifactorial,	in	that	none	of	the	142	
Toledo	sequences	appeared	measurably	to	enhance	virulence	when	inserted	into	the	Towne	genome.	143	
Alternatively,	it	is	possible	that	the	RL13	or	UL128	mutations	present	in	Toledo	passage	8	and	the	144	
chimeras	did	not	fully	pervade	the	viral	population	present	in	the	Toledo	passage	4	or	5	stocks	that	145	
proved	virulent	in	humans;	that	is,	that	some	unmutated	virus	may	have	remained	at	this	stage	and	was	146	
responsible	for	the	biological	effect.	Unfortunately,	Toledo	passage	8	has	not	been	tested	in	humans,	147	
and	samples	of	earlier	passages	are	no	longer	available.	148	
The	construction	and	testing	of	the	four	chimeric	vaccine	candidates	has	provided	a	rare	149	
opportunity	to	study	the	genetics	of	viral	pathogenesis	in	humans.	While	no	specific	virulence	gene	150	
emerged	from	this	limited	study,	the	data	suggest	that	relatively	few	genetic	changes	are	capable	of	151	
producing	a	virus	that	is	highly	attenuated	and	yet	capable	of	replicating	in	vivo	to	an	extent	required	to	152	
induce	both	humoral	and	cellular	immune	responses.	These	findings	may	be	valuable	for	rationally	153	
designing	live	attenuated	or	replication-defective	vaccines	that	maximize	safety	while	optimizing	154	
immunogenicity	and	efficacy.	155	
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Table	1.	Partial	and	complete	genome	sequences	of	HCMV	strains	Towne	and	Toledoa.	247	
	248	
Strain	 Genome	 Accession	 Size	(bp)	 Release	date		 Reference	
Towne	 BAC	varS	 AC146851	 229,483	 14-Oct-2003	 (33)	
Towne	 BAC	varS	 AY315197	 222,047	 01-Dec-2003	 (34)	
Towne	 Virus	varL	 FJ616285	 235,147	 07-Feb-2009	 (9)	
Towne	 BAC	varL	 GQ121041	 238,311	 17-Jun-2009	 (10)	
Towne	 BAC	mutant	(UL96)	varS	 KF493877	 233,028	 18-Aug-2013	 (35)	
Towne	 Virus	mutant	(UL96)	varS	 KF493876	 232,948	 18-Aug-2013	 (36)	
Toledo	 BAC	 AC146905		 226,889	 21-Oct-2003	 (33)	
Toledo	 Virus	 AH013698	 158,133	 08-Mar-2004	 (36)	
Toledo	 Virus	 GU937742	 235,404	 10-Mar-2010	 Present	work	
Toledo	 Virus	variant	 KY002201	 235,681	 15-Nov-2016	 Present	work	
Toledo	 Virus	mutant	(RNA2.7)	 KY002200	 233,779	 15-Nov-2016	 Present	work	
Towne/Toledo	 Virus	chimera	1	 KX101021	 235,882	 08-Jun-2016	 Present	work	
Towne/Toledo	 Virus	chimera	2	 KX101022	 234,441	 08-Jun-2016	 Present	work	
Towne/Toledo	 Virus	chimera	3	 KX101023	 235,354	 08-Jun-2016	 Present	work	
Towne/Toledo	 Virus	chimera	4	 KX101024	 236,269	 08-Jun-2016	 Present	work	
	249	
aGenomes	were	sequenced	as	bacterial	artificial	chromosomes	(BACs),	viruses,	virus	variants,	virus	250	
mutants,	or	virus	chimeras,	and	in	varS	or	varL	form	for	Towne.		The	two	Towne	BAC	varS	sequences	251	
describe	the	same	BAC	but	differ	in	size	because	they	lack	different	parts	of	the	vector.	The	chimeras	252	
that	had	been	used	to	inoculate	seronegative	human	subjects	(13)	were	amplified	by	passaging	twice	in	253	
MRC-5	human	fibroblast	cells,	and	virion	DNA	was	isolated	from	culture	supernatants	as	described	254	
previously	(37).	Sequence	data	were	obtained	for	these	and	the	other	viruses	examined	in	the	present	255	
work	by	using	the	Illumina	MiSeq	platform,	and	assembled	and	validated	as	described	previously	(38).	256	
Additional	information	is	available	in	the	GenBank	accessions.	257	
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Figure	1.	(A)	Sequence-based	genetic	maps	of	the	four	Towne/Toledo	chimera	vaccine	strains.	Open	258	
arrows	indicate	open	reading	frames,	and	lines	with	arrowheads	indicate	noncoding	RNAs.	Tall	259	
rectangles	indicate	inverted	repeats	(a/a’	and	c/c’),	and	these	and	other	features	(oriLyt,	RNA4.9,	IRS1,	260	
and	TRS1)	are	labeled	on	chimera	1.	Genes	containing	disrupting	mutations	are	labeled	in	red,	and	genes	261	
located	at	breakpoints	are	labeled	in	black	(these	include	UL36	in	chimera	2).	Additional	differences	262	
among	regions	derived	from	the	same	original	strain	are	not	marked.	These	include	a	large	noncoding	263	
deletion	between	US34A	and	TRS1	in	chimera	2,	a	small	noncoding	deletion	between	UL150A	and	IRS1	264	
in	chimera	3,	a	short	region	of	Towne	sequence	at	the	beginning	of	the	Toledo	a’	sequence	in	chimera	2	265	
(probably	as	a	result	of	recombination),	a	few	differences	in	the	lengths	of	noncoding	G:C	tracts,	three	266	
substitutions	in	intergenic	regions	(UL102/UL103	and	UL124/UL128	in	chimera	1	and	UL23/UL24	in	267	
chimera	4),	one	substitution	in	RNA5.0	in	chimera	2,	two	synonymous	substitutions	in	coding	regions	268	
(UL10	and	TRS1	in	chimera	1),	four	nonsynonymous	substitutions	(UL11	and	US10	in	chimera	1,	UL47	in	269	
chimera	2	and	UL93	in	chimera	4),	and	a	small	number	(2-6	per	genome)	of	nucleotide	polymorphisms.	270	
The	recombinational	breakpoint	in	US16	in	chimeras	1,	2,	and	3	is	located	in	the	same	255	bp	sequence.	271	
The	values	on	the	right	indicate	the	relative	immunogenicity	levels	of	each	chimera	reported	previously	272	
(13).	(B)	MRC-5	fibroblast	or	ARPE-19	epithelial	cells	were	mock-infected	or	infected	with	equivalent	273	
amounts	of	the	indicated	viruses	and	after	4	d	stained	for	HCMV	immediate	early	proteins	as	described	274	
previously	(27).	BADrUL131	and	TS15-rN	are	epitheliotropic	variants	of	HCMV	strains	AD169	and	Towne	275	
varS,	respectively	(26,	39),	and	TS15	is	a	non-epitheliotropic	variant	of	Towne	varS	(10).			276	
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